Lv3
390 积分 2024-07-04 加入
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
2个月前
已完结
Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung Cancer
3个月前
已完结
Circulating tumor DNA-minimal residual disease: An up-and-coming nova in resectable non-small-cell lung cancer
5个月前
已完结
A HER2-Targeting Antibody–Drug Conjugate, Trastuzumab Deruxtecan (DS-8201a), Enhances Antitumor Immunity in a Mouse Model
6个月前
已完结
Mechanism of action and future perspectives of ADCs in combination with immune checkpoint inhibitors for solid tumors
6个月前
已完结
DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC
8个月前
已完结
Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive, Locally Advanced, or Metastatic Breast Cancer
8个月前
已完结
Dual HER2 inhibition: mechanisms of synergy, patient selection, and resistance
8个月前
已完结
Spatiotemporal Quantification of HER2-targeting Antibody–Drug Conjugate Bystander Activity and Enhancement of Solid Tumor Penetration
8个月前
已完结
Pyrotinib in Patients with HER2-Amplified Advanced Non–Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial
8个月前
已完结
皖公网安备34019202002308
